linagliptin
Selected indexed studies
- Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. (Diabetes Care, 2015) [PMID:25583754]
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. (JAMA, 2019) [PMID:30418475]
- Linagliptin: A comprehensive profile. (Profiles Drug Subst Excip Relat Methodol, 2025) [PMID:39855779]
_Worker-drafted node — pending editorial review._
Connections
linagliptin is a side effect of
Sources
- Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. (2015) pubmed
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. (2019) pubmed
- Linagliptin: A comprehensive profile. (2025) pubmed
- Linagliptin safety profile: A systematic review. (2018) pubmed
- Empagliflozin/Linagliptin: A Review in Type 2 Diabetes. (2015) pubmed
- Linagliptin: from bench to bedside. (2014) pubmed
- Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option. (2015) pubmed
- Linagliptin: a review of its use in the management of type 2 diabetes mellitus. (2012) pubmed
- Safety of Linagliptin in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Clinical Trials. (2024) pubmed
- Linagliptin: in type 2 diabetes mellitus. (2011) pubmed